Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in ...

Now, a pair of Scripps Research Institute scientists has taken a significant step toward answering that question. The scientists have synthesized for the first time RNA enzymes that can replicate ...

Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts Vector improvements demonstrate broad potential of Replicate's srRNA for ...

BUFFALO, N.Y. — The RNA world theory suggests that life on Earth began with RNA molecules that copied themselves. It’s believed this self-replication eventually gave rise over millions of years to DNA ...

The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines The Company is exploring the use of the c-srRNA platform for the development of ...

Salk scientists engineered a right-handed RNA enzyme (bottom left) that can combine left-handed RNA fragments (bottom right) to create a mirror image of itself. The new left-handed RNA enzyme (top ...

Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...

SANTA CRUZ, CA — Researchers at the University of California, Santa Cruz, have determined the three-dimensional structure of an RNA enzyme, or “ribozyme,” that carries out a fundamental reaction ...